A new Ebola testing machine is installed in the laboratory of Mongbwalu General Referral Hospital in Ituri eprovince, DR Congo. The equipment allows samples to be tested on site, reducing the need to transport them to Bunia and helping teams obtain results more quickly during the Ebola response.

Photo Credit: Anna Schönhofer/MSF

08 June 2026

Principles for equitable access to medical tools for Ebola disease caused by Bundibugyo virus

MSF calls for following R&D Principles for equitable access to medical tools for Bundibugyo virus

RESEARCH AND DEVELOPMENT

Photo Credit: Anna Schönhofer/MSF

Statement |

16 June 2026

Europe

European Biotech Act Must Deliver Public-Interest Innovation and Equitable Access

Press release |

16 June 2026

Public investment demands public benefits: European Biotech Act must deliver for people

Events |

18 May 2026

MSF statements at WHO World Health Assembly 79th session

Statement |

18 May 2026

Open-ended Intergovernmental Working Group on the WHO Pandemic Agreement – WHA79/13.3

Statement |

18 May 2026

Follow-up to the political declaration of the high-level meeting of the General Assembly on the prevention and control of non-communicable diseases – WHA79/12.1

Statement |

18 May 2026

Immunization Agenda 2030 – WHA79/12.3

Statement |

18 May 2026

Draft updated global action plan on antimicrobial resistance – WHA79/12.9

Press release |

18 May 2026

Urgent action needed to close devastating vaccination coverage gaps in conflict-affected settings

Statement |

18 May 2026

WHO’s work in health emergencies – WHA79/ 14.1

Press release |

15 May 2026

Countries must lay groundwork to turn Pandemic Agreement commitments into access for all

Statement |

06 May 2026

MSF Access welcomes Kris Torgeson as incoming Executive Director

Letter |

17 April 2026

Open letter: Linking pathogens and data access to enforceable benefit-sharing commitments in the Pandemic Agreement

Salah Aldeen - nurse – places an intravenous line to Marwa, 3 years. Marwa was admitted the day before, as she was presenting common symptoms of measles. Amir, her big brother, who lies in the next tent, was admitted 5 days earlier for the same reason.

Photo Credit: Thibault Fendler/MSF

Press release |

18 May 2026

Urgent action needed to close devastating vaccination coverage gaps in conflict-affected settings

Sustained funding, timely and unhindered access to vaccine supplies, and flexible, secure and adapted delivery models required to reach more people with lifesaving vaccination in world’s most fragile areas

VACCINES

Photo Credit: Thibault Fendler/MSF

Statement |

16 June 2026

Europe

European Biotech Act Must Deliver Public-Interest Innovation and Equitable Access

Press release |

16 June 2026

Public investment demands public benefits: European Biotech Act must deliver for people

Events |

18 May 2026

MSF statements at WHO World Health Assembly 79th session

Statement |

18 May 2026

Open-ended Intergovernmental Working Group on the WHO Pandemic Agreement – WHA79/13.3

Statement |

18 May 2026

Follow-up to the political declaration of the high-level meeting of the General Assembly on the prevention and control of non-communicable diseases – WHA79/12.1

Statement |

18 May 2026

Immunization Agenda 2030 – WHA79/12.3

Statement |

18 May 2026

Draft updated global action plan on antimicrobial resistance – WHA79/12.9

Statement |

18 May 2026

WHO’s work in health emergencies – WHA79/ 14.1

Press release |

15 May 2026

Countries must lay groundwork to turn Pandemic Agreement commitments into access for all

Statement |

06 May 2026

MSF Access welcomes Kris Torgeson as incoming Executive Director

Letter |

17 April 2026

Open letter: Linking pathogens and data access to enforceable benefit-sharing commitments in the Pandemic Agreement

Report |

09 April 2026

AfricaKenyaRwandaSouth Africa

Shifting Global Health R&D Funding: Opportunities in a Changing Landscape

MSF doctor Dr. Maham Khalid is examining four-year-old Ahmad during a consultation at the MSF-supported Programmatic Management of Drug-Resistant Tuberculosis (PMDT) site in Gujranwala, Punjab.

Photo Credit: Gul Nayab

Press release |

24 March 2026

MSF demands sustained investments and political will to end neglect of children with tuberculosis

1.2 million children have TB worldwide, but nearly half miss diagnosis and treatment

TUBERCULOSIS

Photo Credit: Gul Nayab

Statement |

16 June 2026

Europe

European Biotech Act Must Deliver Public-Interest Innovation and Equitable Access

Press release |

16 June 2026

Public investment demands public benefits: European Biotech Act must deliver for people

Events |

18 May 2026

MSF statements at WHO World Health Assembly 79th session

Statement |

18 May 2026

Open-ended Intergovernmental Working Group on the WHO Pandemic Agreement – WHA79/13.3

Statement |

18 May 2026

Follow-up to the political declaration of the high-level meeting of the General Assembly on the prevention and control of non-communicable diseases – WHA79/12.1

Statement |

18 May 2026

Immunization Agenda 2030 – WHA79/12.3

Statement |

18 May 2026

Draft updated global action plan on antimicrobial resistance – WHA79/12.9

Press release |

18 May 2026

Urgent action needed to close devastating vaccination coverage gaps in conflict-affected settings

Statement |

18 May 2026

WHO’s work in health emergencies – WHA79/ 14.1

Press release |

15 May 2026

Countries must lay groundwork to turn Pandemic Agreement commitments into access for all

Statement |

06 May 2026

MSF Access welcomes Kris Torgeson as incoming Executive Director

Letter |

17 April 2026

Open letter: Linking pathogens and data access to enforceable benefit-sharing commitments in the Pandemic Agreement

Maria Atonio, 43-years-old farmer from Macomia, returns home after visiting MSF’s Clinic in Nanga to receive ART treatment and to have a medical appointment with MSF’s clinical officer to monitor her health.

Photo credit: MSF/Martim Gray Pereira

Press release |

19 March 2026

MSF calls on EU to unlock progress in final Pandemic Agreement talks

EU must guarantee access to medical tools for communities sharing pathogens and data

PANDEMIC PREPAREDNESS RESEARCH AND DEVELOPMENT

European Union

Photo credit: MSF/Martim Gray Pereira

Statement |

16 June 2026

Europe

European Biotech Act Must Deliver Public-Interest Innovation and Equitable Access

Press release |

16 June 2026

Public investment demands public benefits: European Biotech Act must deliver for people

Events |

18 May 2026

MSF statements at WHO World Health Assembly 79th session

Statement |

18 May 2026

Open-ended Intergovernmental Working Group on the WHO Pandemic Agreement – WHA79/13.3

Statement |

18 May 2026

Follow-up to the political declaration of the high-level meeting of the General Assembly on the prevention and control of non-communicable diseases – WHA79/12.1

Statement |

18 May 2026

Immunization Agenda 2030 – WHA79/12.3

Statement |

18 May 2026

Draft updated global action plan on antimicrobial resistance – WHA79/12.9

Press release |

18 May 2026

Urgent action needed to close devastating vaccination coverage gaps in conflict-affected settings

Statement |

18 May 2026

WHO’s work in health emergencies – WHA79/ 14.1

Press release |

15 May 2026

Countries must lay groundwork to turn Pandemic Agreement commitments into access for all

Statement |

06 May 2026

MSF Access welcomes Kris Torgeson as incoming Executive Director

Letter |

17 April 2026

Open letter: Linking pathogens and data access to enforceable benefit-sharing commitments in the Pandemic Agreement

Latest News

The first batch of the Ad26.ZEBOV / MVA-BN-Filo vaccine, produced by Janssen / Johnson & Johnson, has arrived in Goma, Democratic Republic of Congo. The start of the study is scheduled for November 14th.

Photograph by Gabriella Bianchi

Press release

Press release |

05 December 2019

Vaccines

MSF response to Gavi announcement on financing of global emergency stockpile of Ebola vaccine

3 min

Interview

Interview |

03 December 2019

Vaccines

NigeriaGreeceSyria

Saving children’s lives with PCV - An interview with Miriam Alia, Vaccination Advisor

6 min

Technical brief |

02 December 2019

Tuberculosis

Time for $5: GeneXpert diagnostic tests

Technical brief |

02 December 2019

Intellectual property and trade

Briefing note for 31st WIPO Standing Committee on the Law of Patents

The pneumonia vaccine from GSK used for vaccination in refugee camps in Greek islands was made available at a special reduced price of US$9 while its retail price is $168 in Greece.

Photograph by Anna Pantelia

Press release

Press release |

02 December 2019

Vaccines

US$262 million subsidy should not go to pharma giants Pfizer and GSK for pneumococcal vaccine

5 min

Report |

29 November 2019

HIV/AIDS

No time to lose: detect, treat and prevent AIDS

From Guidelines to Reality Accelerating Access to Prevention and Treatment of Paediatric HIV

Technical brief |

28 November 2019

HIV/AIDS

From guidelines to reality: Accelerating access to prevention and treatment of paediatric HIV

Health workers analyzing the images on Lita abdomen in female ward at Nsanje District hospital.

Photograph by Isabel Corthier

Feature story

Feature story |

28 November 2019

HIV/AIDS

Malawi

HIV: Stories from Malawi

4 min

Video

Lives Over Profit: a Patient, a Doctor and a Lawyer Take Action

Video |

14 April 2021

100 years of insulin

Video

A Snapshot of the Access Campaign

Lives Over Profit: a Patient, a Doctor and a Lawyer Take Action

100 years of insulin

A Snapshot of the Access Campaign

Our work

COVID-19

Drug-resistant infections

Diabetes

Hepatitis C

HIV/AIDS

Tropical & neglected diseases

Tuberculosis

Vaccines

Patents & intellectual property

Research & development

European Biotech Act Must Deliver Public-Interest Innovation and Equitable Access

Public investment demands public benefits: European Biotech Act must deliver for people

MSF statements at WHO World Health Assembly 79th session

Open-ended Intergovernmental Working Group on the WHO Pandemic Agreement – WHA79/13.3

Follow-up to the political declaration of the high-level meeting of the General Assembly on the prevention and control of non-communicable diseases – WHA79/12.1

Immunization Agenda 2030 – WHA79/12.3

Draft updated global action plan on antimicrobial resistance – WHA79/12.9

Urgent action needed to close devastating vaccination coverage gaps in conflict-affected settings

WHO’s work in health emergencies – WHA79/ 14.1

Countries must lay groundwork to turn Pandemic Agreement commitments into access for all

MSF Access welcomes Kris Torgeson as incoming Executive Director

Open letter: Linking pathogens and data access to enforceable benefit-sharing commitments in the Pandemic Agreement

European Biotech Act Must Deliver Public-Interest Innovation and Equitable Access

Public investment demands public benefits: European Biotech Act must deliver for people

MSF statements at WHO World Health Assembly 79th session

Open-ended Intergovernmental Working Group on the WHO Pandemic Agreement – WHA79/13.3

Follow-up to the political declaration of the high-level meeting of the General Assembly on the prevention and control of non-communicable diseases – WHA79/12.1

Immunization Agenda 2030 – WHA79/12.3

Draft updated global action plan on antimicrobial resistance – WHA79/12.9

WHO’s work in health emergencies – WHA79/ 14.1

Countries must lay groundwork to turn Pandemic Agreement commitments into access for all

MSF Access welcomes Kris Torgeson as incoming Executive Director

Open letter: Linking pathogens and data access to enforceable benefit-sharing commitments in the Pandemic Agreement

Shifting Global Health R&D Funding: Opportunities in a Changing Landscape

European Biotech Act Must Deliver Public-Interest Innovation and Equitable Access

Public investment demands public benefits: European Biotech Act must deliver for people

MSF statements at WHO World Health Assembly 79th session

Open-ended Intergovernmental Working Group on the WHO Pandemic Agreement – WHA79/13.3

Follow-up to the political declaration of the high-level meeting of the General Assembly on the prevention and control of non-communicable diseases – WHA79/12.1

Immunization Agenda 2030 – WHA79/12.3

Draft updated global action plan on antimicrobial resistance – WHA79/12.9

Urgent action needed to close devastating vaccination coverage gaps in conflict-affected settings

WHO’s work in health emergencies – WHA79/ 14.1

Countries must lay groundwork to turn Pandemic Agreement commitments into access for all

MSF Access welcomes Kris Torgeson as incoming Executive Director

Open letter: Linking pathogens and data access to enforceable benefit-sharing commitments in the Pandemic Agreement

European Biotech Act Must Deliver Public-Interest Innovation and Equitable Access

Public investment demands public benefits: European Biotech Act must deliver for people

MSF statements at WHO World Health Assembly 79th session

Open-ended Intergovernmental Working Group on the WHO Pandemic Agreement – WHA79/13.3

Follow-up to the political declaration of the high-level meeting of the General Assembly on the prevention and control of non-communicable diseases – WHA79/12.1

Immunization Agenda 2030 – WHA79/12.3

Draft updated global action plan on antimicrobial resistance – WHA79/12.9

Urgent action needed to close devastating vaccination coverage gaps in conflict-affected settings

WHO’s work in health emergencies – WHA79/ 14.1

Countries must lay groundwork to turn Pandemic Agreement commitments into access for all

MSF Access welcomes Kris Torgeson as incoming Executive Director

Open letter: Linking pathogens and data access to enforceable benefit-sharing commitments in the Pandemic Agreement

Latest News

Our work

MSF Access welcomes Kris Torgeson as incoming Executive Director

MSF Access welcomes Kris Torgeson as incoming Executive Director

MSF Access welcomes Kris Torgeson as incoming Executive Director

MSF Access welcomes Kris Torgeson as incoming Executive Director